Literature DB >> 19644375

Infection control in cystic fibrosis: barriers to implementation and ideas for improvement.

Lisa Saiman1, Elizabeth Garber.   

Abstract

PURPOSE OF REVIEW: This review will focus on recent research documenting baseline adherence to infection control recommendations and barriers to their implementation as experienced by multidisciplinary cystic fibrosis (CF) care providers. In addition, controversies regarding optimal infection control will be discussed. Finally, suggestions to improve infection control in CF will be proposed. RECENT
FINDINGS: Compliance with recent guidelines was assessed for clinical microbiology laboratories and for infection control policies at CF care centers in the United States. Unlike earlier reports, the vast majority of laboratories used selective media for Burkholderia cepacia complex and identified all species of nonlactose fermenting Gram-negative bacilli. Fewer used selective media for Staphylococcus aureus or used agar-based susceptibility testing assays for Pseudomonas aeruginosa. Only 103 (65%) of 158 CF care centers provided written infection control policies for review and these were more likely to address inpatient than outpatient settings. Surveys of healthcare professionals showed that access to a copy of the CF infection control guidelines reduced barriers to adherence to selected infection control practices.
SUMMARY: These data suggest that access to national infection control guidelines and written local policies are critically important to improving infection control for CF.

Entities:  

Mesh:

Year:  2009        PMID: 19644375     DOI: 10.1097/MCP.0b013e328330d974

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  3 in total

1.  Sodium nitrite-mediated killing of the major cystic fibrosis pathogens Pseudomonas aeruginosa, Staphylococcus aureus, and Burkholderia cepacia under anaerobic planktonic and biofilm conditions.

Authors:  Tiffany A Major; Warunya Panmanee; Joel E Mortensen; Larry D Gray; Niel Hoglen; Daniel J Hassett
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

Review 2.  Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.

Authors:  David E Geller; Jeffry Weers; Silvia Heuerding
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2011-03-11       Impact factor: 2.849

3.  Infection control knowledge, beliefs and behaviours amongst cystic fibrosis patients with epidemic Pseudomonas aeruginosa.

Authors:  R Somayaji; B Waddell; M L Workentine; M G Surette; N P Brager; H R Rabin; M D Parkins
Journal:  BMC Pulm Med       Date:  2015-11-05       Impact factor: 3.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.